SOURCE: Faruqi & Faruqi, LLP

Faruqi & Faruqi, LLP

September 10, 2014 16:00 ET

Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses in Excess of $100,000 Investing in Enzymotec Ltd. (ENZY) to Contact the Firm

NEW YORK, NY--(Marketwired - September 10, 2014) - Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Enzymotec Ltd. ("Enzymotec" or the "Company") (NASDAQ: ENZY) of the November 4, 2014 deadline to seek the role of lead plaintiff in a federal securities class action lawsuit filed against Enzymotec, certain executives and directors of Enzymotec, and the underwriters of the Company's initial public offering.

A complaint has been filed in the District of New Jersey on behalf of all persons who purchased or otherwise acquired Enzymotec securities pursuant and/or traceable to the Company's Registration Statement and Prospectus (collectively, the "Registration Statement") issued in connection with Enzymotec's initial public offering on or about September 27, 2013 (the "IPO") and/or between September 27, 2013 through August 4, 2014, inclusive (the "Class Period").

The complaint alleges that the Company and its executives violated federal securities laws with respect to its disclosures concerning its business, operations, and prospects.

Specifically, the action alleges that Enzymotec made materially false and/or misleading statements and/or failed to disclose during the Class Period that: (i) the Company's baby formula business located in China was jeopardized and subject to a rise in volatility and a reduction in revenues; (ii) Enzymotec's Chinese business was subject to material and readily identifiable Chinese compliance regulations; and (iii) one of the Company's joint ventures was subject to liability and decreasing revenues.

On August 5, 2014, Enzymotec announced that there was an increased impact of Chinese government regulations on its sales of infant formula, and disclosed that its financial results were significantly lower than the prior year in almost all respects.

Following this news, the price of the Company's stock declined by $5.87, or over 39%, to close at $9.11 on August 5, 2014.

Request more information now by clicking here: www.faruqilaw.com/ENZY. There is no cost or obligation to you.

Take Action

If you invested in Enzymotec stock or options pursuant and/or traceable to the Company's Registration Statement issued in connection with the IPO and/or between September 27, 2013 through August 4, 2014, and would like to discuss your legal rights, visit www.faruqilaw.com/ENZY. You can also contact us by calling Richard Gonnello toll free at 877-247-4292 or at 212-983-9330 or by sending an e-mail to rgonnello@faruqilaw.com. Faruqi & Faruqi, LLP also encourages anyone with information regarding Enzymotec's conduct to contact the firm, including whistleblowers, former employees, shareholders and others.

Faruqi & Faruqi, LLP is a national law firm which represents investors and individuals in class action litigation. The firm is focused on providing exemplary legal services in complex litigation in the areas of securities, shareholder, antitrust and consumer litigation, throughout all phases of litigation. The firm has an experienced trial team which has achieved significant victories on behalf of the firm's clients. To keep track of the latest securities litigation news, follow us on Twitter at www.twitter.com/MergerActivity or on Facebook at www.facebook.com/FaruqiLaw.

Attorney Advertising. The law firm responsible for this advertisement is Faruqi & Faruqi, LLP (www.faruqilaw.com). Prior results do not guarantee or predict a similar outcome with respect to any future matter. We welcome the opportunity to discuss your particular case. All communications will be treated in a confidential manner.

Contact Information

  • FARUQI & FARUQI, LLP
    369 Lexington Avenue, 10th Floor
    New York, NY 10017
    Attn: Richard Gonnello, Esq.
    rgonnello@faruqilaw.com
    Telephone: (877) 247-4292 or (212) 983-9330